Literature DB >> 29649369

Women with Newly Diagnosed Uterine Fibroids: Treatment Patterns and Cost Comparison for Select Treatment Options.

Machaon M Bonafede1, Scott K Pohlman2, Jeffrey D Miller1, Ellen Thiel1, Kathleen A Troeger2, Charles E Miller3.   

Abstract

The primary objective of this study was to describe surgical treatment patterns among women with newly diagnosed uterine fibroids (UF). A secondary objective was to estimate the medical costs associated with other common surgical interventions for UF. Claims-based commercial and Medicare data (2011-2016) were used to identify women aged ≥30 years with continuous enrollment for at least 12 months before and after a new diagnosis of UF. Receipt of a surgical or radiologic procedure (hysterectomy, myomectomy, endometrial ablation, uterine artery embolization, and curettage) was the primary outcome. Health care resource utilization and costs were calculated for women with at least 12 months of continuous enrollment following a UF surgical procedure. Among women who met selection criteria, 31.7% of patients underwent a surgical procedure; 20.9% of these underwent hysterectomy. An increase was observed over time in the percentage of women undergoing outpatient hysterectomy (from 27.0% to 40.2%) and hysteroscopic myomectomy (from 8.0% to 11.5%). The cost analysis revealed that total health care costs for hysteroscopic myomectomy ($17,324) were significantly lower (P < 0.001) than those for women who underwent inpatient hysterectomy ($24,027) and those for women undergoing the 3 comparison procedures. Hysterectomy was the most common surgical intervention. Patients undergoing inpatient hysterectomy had the highest health care costs. Although less expensive, minimally invasive approaches are becoming more common; they are performed infrequently in patients with newly diagnosed UF. The results of this study may be useful in guiding decisions regarding the most appropriate and cost-effective surgical treatment for UF.

Entities:  

Keywords:  cost comparison; surgical intervention; treatment patterns; uterine fibroids

Mesh:

Year:  2018        PMID: 29649369     DOI: 10.1089/pop.2017.0151

Source DB:  PubMed          Journal:  Popul Health Manag        ISSN: 1942-7891            Impact factor:   2.459


  9 in total

1.  Non-hormonal mediators of uterine fibroid growth.

Authors:  Esra Cetin; Ayman Al-Hendy; Michał Ciebiera
Journal:  Curr Opin Obstet Gynecol       Date:  2020-10       Impact factor: 1.927

2.  Health Care Costs and Treatment Patterns Associated with Uterine Fibroids and Heavy Menstrual Bleeding: A Claims Analysis.

Authors:  Alice Wang; Siting Wang; Charlotte D Owens; Jamie B Vora; Michael P Diamond
Journal:  J Womens Health (Larchmt)       Date:  2021-09-30       Impact factor: 3.017

Review 3.  The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.

Authors:  Piotr Rubisz; Michał Ciebiera; Lidia Hirnle; Magdalena Zgliczyńska; Tomasz Łoziński; Piotr Dzięgiel; Christopher Kobierzycki
Journal:  Int J Mol Sci       Date:  2019-03-06       Impact factor: 5.923

Review 4.  The Role of miRNA and Related Pathways in Pathophysiology of Uterine Fibroids-From Bench to Bedside.

Authors:  Michał Ciebiera; Marta Włodarczyk; Stanisław Zgliczyński; Tomasz Łoziński; Klaudia Walczak; Artur Czekierdowski
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

5.  The INSPIRE Comparative Cost Study: 12-Month Health Economic and Clinical Outcomes Associated with Hysterectomy, Myomectomy, and Treatment with the Sonata System.

Authors:  Elizabeth Brooks; Linda Mihalov; Dipak Delvadia; Joseph Hudgens; Saifuddin Mama; Gretchen E Makai; Matt W Yuen; Carter A Little; Robert L Bauserman; April Zambelli-Weiner; David J Levine
Journal:  Clinicoecon Outcomes Res       Date:  2020-01-08

6.  EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.

Authors:  Hareesh B Nair; Bindu Santhamma; Kalarickal V Dileep; Peter Binkley; Kirk Acosta; Kam Y J Zhang; Robert Schenken; Klaus Nickisch
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

7.  The role of magnetic resonance-guided focused ultrasound in fertility-sparing treatment of uterine fibroids-current perspectives.

Authors:  Michał Ciebiera; Tomasz Łoziński
Journal:  Ecancermedicalscience       Date:  2020-05-06

8.  Contemporary treatment utilization among women diagnosed with symptomatic uterine fibroids in the United States.

Authors:  Nicole Gidaya Bonine; Erika Banks; Amanda Harrington; Anna Vlahiotis; Laura Moore-Schiltz; Patrick Gillard
Journal:  BMC Womens Health       Date:  2020-08-13       Impact factor: 2.809

9.  Efficacy and Safety of the Two Ayurveda Drug Regimens in Uterine Fibroids: A Randomized Single-Blind Clinical Trial.

Authors:  K P K R Karunagoda; P K Perera; H Senanayake; S De Silva Weliange
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-28       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.